Navigation Links
DIA Conference to Explore Global Pharmacovigilance and Risk Management Strategies and Regultory Frameworks
Date:10/28/2008

The Drug Information Association (DIA) will host Safety is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies (December 10-12; Marina Square, Singapore).

Horsham, PA (Vocus) October 28, 2008 -- The field of medical product safety continues to grow in complexity, with both clinical trial safety and post-marketing pharmacovigilance becoming ever more critical in the development and marketed use of medical products. In response, the Drug Information Association (DIA) will host Safety is Global: Contemporary Pharmacovigilance and Medical Product Risk Management Strategies (December 10-12; Marina Square, Singapore).

This unique three-day conference will explore the latest safety-related regulatory initiatives, how to optimally utilize epidemiological, clinical pharmacological and other techniques, state-of-the-art risk management strategies, and how all of this can be pulled together to create a "system." Featured topics will include:

  • Latest international regulatory developments
  • Generating and assessing critical safety data during development
  • Compliance with clinical safety and post-marketing pharmacovigilance regulatory requirements in an evolving global environment
  • Relationship between compliance and quality in safety-related processes and procedures
  • Recent multinational initiatives under the Inte
    '/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
2. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
3. Accuray Incorporated to Speak at Oppenheimer Healthcare Conference
4. First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009
5. CHADD to Host International Conference on AD/HD in Anaheim, CA; Olympian Bruce Jenner to Keynote
6. ResMed to Webcast First Quarter 2009 Earnings Conference Call
7. Endocare to Present at Oppenheimer 19th Annual Healthcare Conference
8. U.S. Preventive Medicine(R) to Preview The Prevention Plan(TM) at National Conference for Health Care Technology Innovators
9. Weight Watchers Announces Third Quarter 2008 Earnings Conference Call
10. American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference
11. AMN Healthcare Services to Present at the BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DIA Conference to Explore Global Pharmacovigilance and Risk Management Strategies and Regultory Frameworks
DIA Conference to Explore Global Pharmacovigilance and Risk Management Strategies and Regultory Frameworks
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4